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Contemporary inﬂuenza A H3N2 viruses circulating since 2016 have acquired a
glycosylation site in the neuraminidase in close proximity to the enzymatic
active site. Here, we investigate if this S245N glycosylation site, as a result of
antigenic evolution, can impact binding and function of human monoclonal
antibodies that target the conserved active site. While we ﬁnd that a reduction
in the inhibitory ability of neuraminidase active site binders is measurable, this
class of broadly reactive monoclonal antibodies maintains protective efﬁcacy
in vivo.

H1N1, H3N2, and type B seasonal inﬂuenza viruses cause a large
number of infections and deaths annually1. Typically, inﬂuenza
seasons that are dominated by H3N2 viruses are worse in terms of
disease outcome, number of hospitalizations, and are especially
concerning for at-risk populations such as the elderly or younger
children2. In recent years, matching the H3N2 vaccine component
to actual circulating H3N2 viruses has been particularly challenging due to the occurrence of mutations in the hemagglutinin (HA)
during the vaccine production process in eggs3,4 and the emergence of genetically different co-circulating H3N2 clades5. In
addition, the introduction of an N-linked glycosylation site at
residue 245 of the neuraminidase (NA) contributed to antigenic
drift6 and resulted in the blocking of monoclonal and human
serum NA-speciﬁc antibodies7. Therefore, broadly protective,

universal inﬂuenza vaccines8 or improved classical seasonal vaccine formulations are urgently needed9. Such efforts are informed
by the structural and functional characterization of antibodies that
target broadly neutralizing epitopes on the inﬂuenza virus NA. A
double mutation in the NA of inﬂuenza A H3N2 viruses, which leads
to changes in amino acids at positions 245 and 247, was ﬁrst
detected in 2014 and, by 2016/17, almost all circulating H3N2
viruses in humans carried these mutations that introduced an
N-glycosylation site at Asn245, as mentioned above6. These
mutations have become ﬁxed in circulating H3N2 viruses and the
introduced glycan might then contribute to the shielding of certain epitopes.
Here, we test three previously described broadly protective
inﬂuenza virus NA monoclonal antibodies (mAbs)10 against a panel of
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Fig. 1 | Phylogenetic tree of N2 NA of H3N2 viruses and functional characterization of NA-speciﬁc antibodies. A Phylogenetic tree of N2 NAs. The scale bar
represents a 1% change in nucleotides. The tree was built using nucleotide
sequences in ClustalOmega and visualized in FigTree. Vaccine virus strains and
other strains tested in this study are indicated. The H3N2 clade (based on HA), the
amino acid residues at position 245–247, and all predicted potential glycosylation
sites are shown. B Scale bar for the IC50 in μg/ml of viruses tested as shown in the
heatmap. C Heatmap of IC50 of three NA antibodies and irrelevant IgG control mAb.
IC50 values shown were measured in ELLAs except for viruses A/New York City/
PV00033/2017 and A/New York City/PV00077/2017, were the inhibitory

concentrations were determined in an NA-Star assay because of low NA activity in
the ELLA. The antibodies were tested against the viruses in duplicate and the
average of the two measurements was used to calculate the IC50 values depicted.
D Weight loss curves of DBA/2 J mice challenged with reassortant H6N2 viruses. The
data are presented as the mean of the group (n = 5 per group, except for the middle
panel where the n in the irrelevant control IgG group was 4) with error bars indicating the standard error of the mean. Percent survival upon virus challenge is
indicated in parenthesis and the dashed line represents 75% of the initial body
weight, which was deﬁned as the humane endpoint. The experiment was performed
once. Source data are provided as a Source Data ﬁle.

H3N2 viruses, including inﬂuenza virus vaccine strains and clinical
H3N2 isolates (Fig. 1A and Supplementary Fig. 1). We show, that a
reduction in the inhibitory ability of these mAb active site binders is
measurable against viruses harboring the Asn245 glycosylation site but
that this class of broadly reactive antibodies maintains protective
efﬁcacy in vivo.

different extents, the NA activity of various clinical H3N2 virus
isolates (grown in cell culture) that were cultured from nasopharyngeal swab specimen obtained from patients seeking care at
the Mount Sinai Hospital in the years 2017 to 2019 (Fig. 1C). Here
we selected antigenically distinct clinical virus isolates based on
the N2 neuraminidase sequence for testing to cover a broad range
of circulating H3N2 viruses. The 50% inhibitory concentration
(IC50) values of the antibodies tested against viruses without the
glycan [A/Hong Kong/4801/2014 (Hong Kong14) and A/New York
City/PV00077/2017] were lower (0.01-0.69 ug/mL)) compared to
viruses that harbor the glycan (0.60–35.62 ug/mL). Antibody 1E01
had the lowest IC50 across the viruses tested, followed by 1G01,
which was previously shown to be the most cross-reactive of the
three antibodies, and 1G04 (Fig. 1C). Interestingly, in some cases,
differences between mAbs become apparent only in the NI assay
but not in the ELISA. This could be due to differences in glycan size
between recombinant proteins produced in insect cells and viruses grown in cells or embryonated eggs11.

Results
Enzymatic-site targeting mAbs recognize and inhibit drifted
N2 NA
We found that the three NA mAbs could bind to recombinant N2
NAs (produced in the baculovirus system) of three recent inﬂuenza
virus vaccine strains that harbor the S245N glycosylation site in
enzyme-linked immunosorbent assays (ELISAs) (Supplementary
Fig. 2) and that the antibodies can inhibit the NA enzymatic activity
of vaccine strain viruses (grown in eggs) as measured in enzymelinked lectin assays (ELLAs) (Fig. 1C, Supplementary Fig. 2, and
Source Data ﬁle). Further, the three antibodies inhibited, to
Nature Communications | (2022)13:7864
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1G01-like mAbs maintain in vivo protection against drifted
N2 NA
Next, we investigated the protective efﬁcacy of the antibodies in passive transfer and viral challenge experiments in DBA/2 J mice using
reassortant viruses that all contain the same avian H6 HA but different
N2 NAs. The ﬁrst virus carried the wild-type N2 NA of the Hong Kong14
virus (no glycan at position 245). The second virus expressed the Hong
Kong14 N2 NA but with amino acid changes at positions 245 (S245N)
and 247 (S247T) that introduce a glycosylation site and a change at
some distance from the catalytic active site at position 267 (T267K)
that is also present in the N2 NA of A/Singapore/INFIMH-16-0019/2016
(Singapore16). The third virus was an H6 reassortant virus with the N2
NA of Singapore16 that harbors the glycosylation site naturally6. To
conﬁrm the presence of the additional glycan on the Singapore16
N2 NA expressing virus grown in eggs or cell culture, peptide:N-glycosidase F (PNGaseF) treatment followed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blotting was performed (Supplementary Fig. 3). The SDS-PAGE indicates the presence of an additional glycosylation site on the Singapore16 N2 NA when compared to the Hong Kong14 N2 NA, and
PNGaseG treatment removes glycans allowing the NA proteins to run
at the same size on the SDS-PAGE. These differences in glycosylation
sites are similar to those previously shown by others6,12.
The three antibodies were given intraperitoneally at a concentration of 5 mg/kg 2 h prior to challenge and conferred full protection against morbidity (Hong Kong14 virus without or with
artiﬁcially introduced 245 glycosylation site) or mortality (Singapore16
virus with glycosylation site) (Fig. 1D) compared to the control groups.
Interestingly, the functional capacity of the antibodies in vitro in ELLAs
displayed stark differences between the viruses with or without the
glycan (Supplementary Fig. 4) that were not recapitulated in the mouse
model. This ﬁnding could be explained by the contribution of Fceffector functions, such as antibody-dependent cellular cytotoxicity
(ADCC) or antibody-dependent cellular phagocytosis (ADCP), to protective efﬁcacy in vivo, by differences in how the epitope is displayed in
the respective test system, or could indicate that only very low neuraminidase inhibition (NI) activity is needed for protection in vivo.
Furthermore, the glycan at NA Asn245 has been shown to reduce NA
enzymatic activity7. The reduced activity is controlled for in the in vitro
experiments to measure IC50s; however, reduced NA activity in the
in vivo experiments might be another reason for the discordance of
measured IC50s and in vivo protective effects.

Structural characterization of the mAb-drifted N2 interaction
To illustrate the location of the glycan in the context of the
antigen–antibody interaction, we modeled the complex of the Singapore16 N2 NA with the antibody binding fragment (Fab) of 1G01. Based
on the modeling results in combination with the binding, NI and protection data, we concluded that 1G01 is still able to bind to Singapore16
N2 NA with the additional Asn245 glycosylation (Fig. 2A), although the
glycan attached at NA Asn245 could potentially form transient interactions with 1G01. As a control, we also modeled the complex of the
Hong Kong14 N2 NA with 1G01 Fab (Fig. 2A), where the only difference
in the 1G01 epitope was at N245 and T247 that encodes the 245 glycosylation site in Singapore16 N2 NA as compared to S245 and S247 in
Hong Kong14 N2 NA. Similarly, antibodies 1E01 and 1G04 also appear
able to bind Singapore16 N2 NA with the additional Asn245 glycosylation (Supplementary Fig. 5). Further, we conﬁrmed the modeling
results by performing negative-stain electron microscopy (nsEM) studies (Fig. 2B and Supplementary Fig. 6). Examination of 2D class
averages from the nsEM images for complexes of Singapore16 N2 NA
with Fabs 1G01, 1G04, or 1E01 showed that one Fab bound to the active
site of each N2 NA protomer (i.e., four Fabs per NA tetramer) (Fig. 2B).
In 3D reconstructions, antibodies 1G01, 1G04, and 1E01 were found to
bind to Singapore16 N2 NA in a similar manner to binding to N1 NA

Nature Communications | (2022)13:7864

https://doi.org/10.1038/s41467-022-35586-7

from A/California/04/2009 (H1N1) (Cali04), Hunan16 N9 NA from A/
Hunan/02650/2016 (H7N9) (Hunan16), and N2 NA from A/Japan/305/
1957 (H2N2) (Japan57)10, respectively, in which the 1G01, 1G04, and
1E01 epitopes consisted mostly of conserved active site residues of the
NAs (Fig. 2B). Sequence comparison of the 1E01 epitope in Japan57 N2
NA, as well as the 1G01 epitope in Cali04 N1 NA and the 1G04 epitope in
Hunan16 N9 NA, with Hong Kong14 N2 NA and Singapore16 N2 NA
indicated that the their epitopes are quite conserved in these N2 NAs
(Supplementary Figs. 7, 8, 9). Notwithstanding, the epitope differences
between these three antibodies to N2 NA (Supplementary Figs. 7, 8, 9),
the potential different angles of the approach of these antibodies to N2
NA (Supplementary Fig. 10), as well as the sequence differences
between these antibodies10, may contribute to the differences in their
binding to NA and NA inhibition efﬁcacy (Fig. 1 and Supplementary
Figs. 1, 2, 4).

Discussion
In summary, we demonstrate that broadly protective human antibodies that target the active site of the inﬂuenza virus NA can maintain
binding, functionality, and protective efﬁcacy against contemporary
H3N2 viruses with an S245N glycosylation site. In previous studies,
antigenic drift was observed in the NAs of recent viruses with a
reduction in NI titers of human sera against these NAs and a loss of
in vivo protection in passive transfer studies; substantially reduced
binding of NA-speciﬁc mAbs was also demonstrated6. However, the
introduction of the S245N glycan into the N2 NA did not prevent the
binding of 1G01 and 1G01-like mAbs that directly target the NA active
site, as conﬁrmed by electron microscopy. Of note, NI activity of
human polyclonal serum was also not completely abrogated, although
signiﬁcantly reduced, in earlier studies, perhaps suggesting the presence of 1G01-like antibodies in serum that maintain activity. Of
course, the inhibiting antibody response to NA is not restricted to the
active site and antibodies to other epitopes may contribute to this
residual activity. Our ﬁndings showing the continued activity of 1G01like antibodies against drifted N2 NA, in combination with the exclusive breadth across NA subtypes, further highlight the value of these
particular antibodies as possible prophylactic or therapeutic agents. In
addition, developing vaccines that can elicit 1G01-like antibodies
would allow for protection against drifted viruses and broad protection in general.

Methods
Our research conforms to all ethical regulations. Speciﬁcally, animal
experiments were conducted in compliance with protocols approved
by the Icahn School of Medicine at Mount Sinai’s Institutional Animal
Care and Use Committee.

Cells, proteins, and viruses
Madin Darby canine kidney (MDCK, source ATCC) cells were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco) containing FBS
(fetal bovine serum, 10%; Corning) and penicillin–streptomycin antibiotics mix (pen-strep antibiotics mix, 100 μg/mL streptomycin,
100 U/mL of penicillin; Gibco) resulting in complete DMEM (cDMEM).
Human embryonic kidney (HEK) cells (293 T, source ATCC) were
grown and maintained in cDMEM. HEK 293 F cells (Thermo Fisher)
were grown in Expi293 Expression medium (Gibco). BTI-TN−5B14 cells (Trichoplusia ni, source Vienna Institute of Biotechnology,
University of Natural Resources and Life Sciences) were grown in
serum-free SFX medium (HyClone) supplemented with penstrep antibiotics mix . Sf9 cells (Spodoptera frugiperda, source Vienna
Institute of Biotechnology, University of Natural Resources and Life
Sciences) were maintained in TNM-FH medium (Gemini Bio-Products)
in the presence of pen-strep antibiotics mix and 10% FBS. Vaccine
strains and reassortant viruses were grown in 8–10-day-old embryonated chicken eggs (Charles River Laboratories) at 37 °C (inﬂuenza A
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Fig. 2 | Model of the complex of Singapore16 and Hong Kong14 N2 NAs with
1G01 Fab and negative-stain electron microscopy of antibodies 1G01, 1G04,
and 1E01 bound to Singapore16 N2 NA. A The Singapore16 N2 NA was modeled
with a mannose-9 glycan at Asn245. The 1G01 Fab is able to interact with the N2 NA
(left). The glycan can be accommodated without steric clash with the 1G01 Fab.
A model of the interaction of 1G01 Fab to Hong Kong14 N2 NA is also shown (right).
NA protomers are colored green. Asn245 and attached glycans, as well as the ten
residues that are not conserved between these two N2 NAs in their ectodomain
(82–469) are shown in sticks and colored with yellow carbon, red oxygen and blue
nitrogen atoms. The 1G01 Fab is colored brown (heavy chain) and gray (light chain).

B Two-dimensional class averages of Singapore16 N2 NA in complex with 1G01,
1G04, and 1E01 Fabs (Top). Standard view (middle) and side view (bottom) of threedimensional reconstruction of negative-stain EM maps of Singapore16 N2 NA tetramer (center, in green) in complex with four 1G01 Fabs (in orange), four 1G04 Fabs
(in yellow), and 1E01 Fabs (in cyan), respectively (densities with a dimple on the
periphery). The crystal structures of 1G01 Fab (PDB code 6Q23), 1G04 Fab (PDB
code 6Q1Z), and 1E01 Fab (PDB code 6Q20) and the Singapore16 N2 NA tetramer
model were docked into the reconstruction, respectively, and the Fabs were
adjusted individually to best ﬁt the EM density.

viruses) for 2 days. Virus reassortants used in this study were rescued
by plasmid-based reverse genetic techniques as previously described
in refs. 6, 13. All reassortant viruses bear the internal genes from A/
Puerto Rico/8/1934 H1N1. Primary virus isolates were obtained from
discarded nasopharyngeal specimens that tested positive for inﬂuenza

virus infection. Brieﬂy, specimens were pre-diluted in infection media
consisting of Minimum Essential Media (Gibco) supplemented with
1 µg/ml of tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)treated trypsin (Gibco) and added to 90% conﬂuent MDCK cellmonolayers. Infections were let to proceed for 1 h with intermittent
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shaking. The inoculum was removed and infection media was added.
Plates were incubated at 37 °C with 5% CO2 and supernatants were
collected at 24–48 hpi when a cytopathic effect was detected. Samples
were cleared by centrifugation at 4300 × g for 5 min and aliquoted
through 0.22 µm pore size membrane ﬁlters (Millipore). Supernatants
were stored at −80 °C until further use and viruses were sequenced
after culture. To purify viruses for binding assays, viruses were grown
in eggs or in cell culture and puriﬁed over a 30% sucrose cushion.
Recombinant proteins were expressed in the baculovirus
expression system as previously described in detail in ref. 14. All NAs
were expressed as ectodomains with an N-terminal vasodilatorstimulated phosphoprotein (VASP) tetramerization domain and a
hexahistidine tag for puriﬁcation.

Monoclonal antibody generation and puriﬁcation
Heavy and light chain plasmids were co-transfected into Expi293F cells
for expression and antibodies were puriﬁed via sepharose G columns
(GE Healthcare)10. The antibody sequences have been uploaded on
GenBank (accession numbers: MN013068 (1G01 VH), MN013072 (1G01
Vκ), MN013070 (1E01 VH) MN013070 (1E01 Vκ), MN013069 (1G04 VH),
and MN013073 (1G04 Vκ). The heavy and light chain plasmids of an
irrelevant human IgG control monoclonal antibody were cotransfected and puriﬁed similarly.

Enzyme-linked immunosorbent assay
Microtiter 96-well plates (Thermo Fisher) were coated with 50 μL
recombinant NA at a concentration of 2 μg/mL in phosphate-buffered
saline (PBS; Gibco) at 4 °C overnight. The following day, 220 μL
blocking solution (PBS (Gibco) supplemented with 0.1% Tween 20
(Fisher Scientiﬁc), 3% goat serum (Life Technologies), and 0.5% milk
powder (American-Bio)) was added to all wells and the plates were
incubated for 1 h at room temperature. The antibodies were diluted to
a starting concentration of 30 μg/mL, serially diluted 1:3 in blocking
solution, and incubated for 2 h in a room temperature incubator. The
microtiter plates were washed three times with T-PBS (PBS (Gibco)
supplemented with 0.1% Tween 20 (Fisher Scientiﬁc)) and 50 μL goat
anti-human IgG (Fab speciﬁc) horseradish peroxidase antibody (HRP;
Sigma, #A0293) diluted 1:3000 in blocking solution was added to
all wells and incubated for 1 h at room temperature. The plates
were washed four times with shaking and 100 μL SigmaFast
o-phenylenediamine dihydrochloride (OPD; Sigma) was added to all
wells. After 10 min, the reaction was stopped with 50 μL 3 M hydrochloric acid (Thermo Fisher) and the plates were read at a wavelength
of 490 nm with a plate reader (BioTek). The data were analyzed in
Microsoft Excel and GraphPad Prism 7. The data were visualized as
binding curves by applying a nonlinear ﬁt.

Enzyme-linked lectin assay
Ninety-six-well microtiter plates (Thermo Fisher) were coated with
100 μL/well fetuin (Sigma) at a concentration of 25 μg/mL in PBS at
4 °C overnight. To determine the amount of virus to use in the assay,
the viruses were serially diluted twofold in sample diluent (PBS (Gibco)
with 0.9 mM CaCl2 and 0.5 mM MgCl2 supplemented with 1% bovine
serum albumin (MP Biomedicals) and 0.5% Tween 20 (Fisher Scientiﬁc)) in cell culture 96-well plates. The fetuin plates were washed three
times with T-PBS and 100 ul of the diluted viruses transferred into the
fetuin plates. The plates were incubated for 18 h at 37 °C and washed
three times with T-PBS and HRP-conjugated peanut agglutinin (PNA) in
PBS was added (100 ul/well) to the plates. The plates were incubated at
RT for 2 h and washed four times with shaking and developed with
SigmaFast OPD. Absorbance was read at 490 nm on a microplate
reader. The data were analyzed using GraphPad Prism 8 and the 50%
effective concentration (EC50) was calculated based on four-parameter
nonlinear regression. The dilution of the virus that resulted in 2x the
EC50 was chosen for the subsequent NA inhibition assay.
Nature Communications | (2022)13:7864
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To measure the inhibitory concentration of the antibodies, the
antibodies were serially diluted in sample diluent (starting concentration 30 ug/ml) and incubated for 18 h at 37 °C with an equal
volume (50 ul) of the selected virus dilution in the fetuin-coated plates.
The remainder of the assay was performed as described above. One
column on the plate contained sample diluent without antibodies and
served as a positive (virus-only) control. Another column contained
sample diluent only (no virus) and served as negative (background)
control. Data were analyzed in GraphPad Prism 8 and the 50% inhibitory concentration (IC50) was calculated based on nonlinear regression
using a four-parameter curve ﬁt.

NA-Star assay
The NA-Star assay was performed for viruses that had low NA activity
in the ELLA. The NA-Star can measure NA activity with higher sensitivity. The antibodies tested in the present study target the NA active
site directly, which makes it possible to use the NA-Star assay for the
determination of NAI. Typically, the NA-Star kit is used to detect
resistance to neuraminidase inhibitors (e.g. small molecules). The NAStar Inﬂuenza Neuraminidase Inhibitor Resistance Detection Kit
(Applied Biosystems) was used according to the manufacturer’s protocol. In brief, the antibodies were diluted to a concentration of 30 ug/
ml, serially diluted twofold in assay buffer, and 25 ul transferred to a
white 96-well cell culture plate. Twenty-ﬁve ul of virus diluted to
2xEC50 (as determined in prior assays testing the respective viruses in
the absence of antibodies) was added to each well and the plates were
incubated for 20 min at 37 °C with shaking. The NA-Star substrate was
prepared immediately before use and 10 ul/well was added to all wells.
The plates were incubated for 30 min at RT and 60 ul/well of NA-Star
accelerator solution was added shortly before reading the plates using
a microtiter plate reader (BioTek). The data were analyzed in GraphPad
Prism 8 and the inhibition curves were plotted.

PNGaseF treatment, SDS-PAGE, and Western blot
Puriﬁed viruses were treated using the PNGaseF kit (NEB) according to
the manufacturer’s instructions. The samples were then treated with
4X-Laemli buffer (Bio-Rad) containing beta-mercaptoethanol (BME)
and heated at 100 °C for 5 min. Approximately 1 ug puriﬁed virus was
added to each lane on a 7.5% Mini-PROTEAN® TGX™ precast protein gel
(Bio-Rad) and run for 5.5 h at 25 V. After electrophoresis, the proteins
were transferred to a nitrocellulose membrane using the iBlot transfer
and stack device (Invitrogen) at 20 V for 7 min. The membranes were
blocked in 5% nonfat dry milk (Bio-Rad) in PBS-T (0.5%) for 1 h at room
temperature with shaking. The blocking solution was removed and
anti-N2 guinea pig antisera (generated in-house by vaccinating guinea
pigs intramuscularly with Hong Kong14 N2 recombinant protein)
diluted 1:2000 in PBS supplemented with 1% (w/v) BSA was added. The
membranes were incubated overnight and washed three times with
PBS-T. The following day, a donkey anti-guinea pig IgG-horseradish
peroxidase conjugate (IgG-HRP; EMD Millipore, AP193P) was added for
1 h at room temperature and the membranes were washed. The
membranes were developed by adding ECL prime and incubated for
5 min. The developed blot membranes were visualized by scanning
using an ImageScanner III imager with accompanying LabScan software (GE Healthcare).

Passive transfer experiments in mice
Animal experiments were conducted in compliance with protocols
approved by the Icahn School of Medicine at Mount Sinai’s Institutional Animal Care and Use Committee. Mice were housed in a facility
with a 12 h light/dark cycle, room temperature, relative humidity
between 20 and 30% and access to food ad libitum. Passive transfer
experiments to test the prophylactic efﬁcacy of the mAbs were performed as described earlier10. In brief, 6–8 weeks-old female DBA/2 J
mice (n = 5 mice/group except for Fig. 1D in the middle panel in the
5
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irrelevant IgG control where n = 4; mice were sourced from The Jackson Laboratory) were given antibody 1G01, 1E01, and 1G04 at a concentration of 5 mg/kg or an irrelevant human IgG control antibody at
the same dose intraperitoneally in a volume of 100 ul. Two hours post
transfer, the mice were anesthetized with a ketamine-xylazine-water
mixture (0.15 mg ketamine/kg and 0.03 mg/kg xylazine of body
weight; 100 μl intraperitoneally) and challenged intranasally with
10 × the 50% mouse lethal dose (mLD50) of the respective challenge
virus. H6N2 reassortant viruses were used in this study because of their
ability to cause disease in the DBA/2 J mouse model. Weight loss was
monitored daily for 14 days and the humane endpoint was deﬁned as a
loss of 25% of the initial day 0 body weight. The data were recorded in
Microsoft Excel and the weight loss and survival graphs were visualized
in GraphPad Prism 8.

Modeling of Singapore16 and Hong Kong14 N2 NAs in complex
with 1G01 Fab
The head domains of N2 NAs (residues 82–469) from A/Singapore/
INFIMH-16-0019/2016 (H3N2) (Singapore16 N2, GISAID14 accession
number EPI810155) and A/Hong Kong/4801/2014 (H3N2) (Hong
Kong14 N2, GISAID accession number EPI675797) were modeled by
MODELER15 using a crystal structure of the N2 NA from A/Tanzania/
205/2010 (H3N2) (PDB ID 4GZO, 2.6 Å resolution16) as a template, with
which Singapore16 N2 NA and Hong Kong14 N2 NA share 97.4 and
98.5% amino acid identity, respectively. A model of the complex
between Singapore N2 NA and 1G01 Fab was constructed in Coot17
using the crystal structure of the N1 NA from A/California/04/2009
(H1N1) (Cali04 N1) in complex with 1G01 (PDB ID 6Q23, 3.27 Å
resolution10) as a template by superimposing the model of Singapore
N2 NA to the Cali04 N1 NA; a mannose-9 glycan was modeled at Asn245
for illustration, although the glycosylation type (high mannose or
complex) is not known. A model of the complex between Hong Kong14
N2 NA and 1G01 Fab was also constructed in Coot17 as above by
superimposing the model of Hong Kong14 N2 NA to the Cali04 N1 NA.
Furthermore, models of the complexes between Singapore16 N2 NA
and 1E01 or 1G04 Fabs were also constructed in Coot17 as above using
the crystal structures of 1E01 Fab with N2 NA from A/Japan/305/1957
(H2N2) (Japan57, PDB ID 6Q20, 2.45 Å resolution10) and 1G04 Fab with
N9 NA from A/Hunan/02650/2016 (H7N9) (Hunan16, PDB ID 6Q1Z,
3.45 Å resolution10), respectively.

Negative stain electron microscopy studies of Singapore16 N2 in
complex with broadly-protective anti-NA antibodies 1G01, 1G04,
and 1E01
The head domain of the N2 NA (residues 82–469) from Singapore16
with a VASP tetramerization domain was cloned and expressed using
the baculovirus system in Sf9 cells essentially as previously described
in ref. 18. Singapore16 N2 NA without VASP tetramerization domain
was obtained by thrombin cleavage of the puriﬁed Singapore16 N2 NA
with the VASP tetramerization domain. Broadly protective anti-NA
antibody Fabs 1G01, 1G04, and 1E10 were expressed in mammalian
ExpiCHO cells as previously reported10.
Antibody 1G01 and 1E01 Fabs were added in 4 M excess to
Singapore16 N2 NA without the VASP tetramerization domain, and
1G04 Fab was added in 4 molar excess to Singapore16 N2 NA with
the VASP tetramerization domain. The N2-Fab complexes were
incubated overnight at 4 °C and directly added to 400 mesh
carbon-covered copper grids and stained with 2% uranyl formate.
The grids were imaged on a Tecnai TF20 equipped with a TVIPS
4k × 4k camera or a Talos Arctica single tilt equipped with a 4k × 4k
Ceta camera. Micrographs were collected using Leginon19 and
uploaded to Appion20 for processing. Particles were picked using
DoGpicker21 and stacked particles were put into Relion22 for 2D
classiﬁcation and 3D classiﬁcation. Chimera23 was used to dock the
individual crystal structures of Fabs 1G01 (PDB code 6Q23), 1G04
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(PDB code 6Q1Z), and 1E10 (PDB code 6Q20) and the Singapore16
N2 NA tetramer model into 3D EM maps.

NA sequences
The sequences for the generation of the phylogenetic tree were
downloaded from the Inﬂuenza Resource Database (www.ﬂudb.org) or
the Global Initiative on Sharing Avian Inﬂuenza Data (www.gisaid.org).
The primary H3N2 virus isolates were sequenced in-house and the
sequences were provided by the Mount Sinai Pathogen Surveillance
Program. These were then uploaded to GISAID and Genbank
(see below).

Reporting summary
Further information on research design is available in the Nature
Portfolio Reporting Summary linked to this article.

Data availability
Data supporting our work are available in the paper and Supplementary
Figs. 1–10. Source data are provided with this paper. Virus sequences
used are available the Global Initiative on Sharing Avian Inﬂuenza Data
(www.gisaid.org and/or at Genbank): A/New York City/PV00077/2017
(EPI_ISL_4073021, NA:MW651812,NP:MW651813,NS:MW651814,PB2:MW651815,HA:MW651816,PA:MW651817,M:MW651818,PB1:MW651819),
A/New York City/PV00012/2017 (EPI_ISL_4062122, PB2:OP872033,PB1:OP872034,PA:OP872035,HA:OP872036,NP:OP872037,NA:OP8720
38,M:OP872039,NS:OP872040), A/New York City/PV00034/2017 (EPI_
ISL_15842142, PB2:OP871889,PB1:OP871890,PA:OP871891,HA:OP8718
92,NP:OP871893,NA:OP871894,M:OP871895,NS:OP871896),
A/New
York City/PV00109/2017 (EPI_ISL_15842162, PB2:OP871905,PB1:OP87
1906,PA:OP871907,HA:OP871908,NP:OP871909,NA:OP871910,M:OP
871911,NS:OP871912), A/New York City/PV00088/2017 (EPI_ISL_15842
180, PB2:OP871913,PB1:OP871914,PA:OP871915,HA:OP871916,NP:OP87
1917,NA:OP871918,M:OP871919,NS:OP871920), A/New York City/PV00
100/2017 (EPI_ISL_15842199, PB2:OP871977,PB1:OP871978,PA:OP8719
79,HA:OP871980,NP:OP871981,NA:OP871982,M:OP871983,NS:OP8719
84), A/New York City/PV00033/2017 (EPI_ISL_4073067, NA:MW6518
20,M:MW651821,PB2:MW651822,NS:MW651823,PA:MW651824,PB1:MW651825,NP:MW651826,HA:MW651827), A/New York City/PV00068/
2017 (EPI_ISL_15842216, PB2:OP871921,PB1:OP871922,PA:OP871923,HA
:OP871924,NP:OP871925,NA:OP871926,M:OP871927,NS:OP871928), A/
New York City/PV00306/2017 (EPI_ISL_15842235, PB2:OP872025,PB1:OP872026,PA:OP872027,HA:OP872028,NP:OP872029,NA:OP8720
30,M:OP872031,NS:OP872032), A/New York City/PV00328/2017 (EPI_
ISL_15842254, PB2:OP871985,PB1:OP871986,PA:OP871987,HA:OP8719
88,NP:OP871989,NA:OP871990,M:OP871991,NS:OP871992),
A/New
York City/PV01148/2018 (EPI_ISL_326910, PB2:OP872017,PB1:OP8720
18,PA:OP872019,HA:OP872020,NP:OP872021,NA:OP872022,M:OP87
2023,NS:OP872024), A/New York City/PV00528/2018 (EPI_ISL_326929,
PB2:OP871969,PB1:OP871970,PA:OP871971,HA:OP871972,NP:OP8719
73,NA:OP871974,M:OP871975,NS:OP871976), A/New York City/PV00
058/2017 (EPI_ISL_15842270, PB2:OP871937,PB1:OP871938,PA:OP8719
39,HA:OP871940,NP:OP871941,NA:OP871942,M:OP871943,NS:OP8719
44), A/New York City/PV00073/2017 (EPI_ISL_15842280, PB2:OP871961,
PB1:OP871962,PA:OP871963,HA:OP871964,NP:OP871965,NA:OP8719
66,M:OP871967,NS:OP871968), A/New York City/PV00190/2017 (EPI_
ISL_15842288, PB2:OP871945,PB1:OP871946,PA:OP871947,HA:OP8719
48,NP:OP871949,NA:OP871950,M:OP871951,NS:OP871952), A/New York
City/PV02895/2019
(EPI_ISL_15842298,
PB1:MW650793,HA:
MW650794,PB2:MW650795,M:MW650796,NP:MW650797,PA:MW6
50798,NA:MW650799,NS:MW650800), A/New York City/PV01536/2018
(EPI_ISL_4072967, PB2:MW651804,NS:MW651805,PB1:MW651806,PA:
MW651807,NP:MW651808,HA:MW651809,M:MW651810,NA:MW6518
11), A/New York City/PV00072/2017 (EPI_ISL_15842308, PB2:OP8720
41,PB1:OP872042,PA:OP872043,HA:OP872044,NP:OP872045,NA:OP87
2046,M:OP872047,NS:OP872048), A/New York City/PV00009/2017
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(EPI_ISL_15842318, PB2:OP872001,PB1:OP872002,PA:OP872003,HA:OP
872004,NP:OP872005,NA:OP872006,M:OP872007,NS:OP872008), A/
New York City/PV00098/2017 (EPI_ISL_15842329, PB2:OP871929,PB1:
OP871930,PA:OP871931,HA:OP871932,NP:OP871933,NA:OP871934,M:
OP871935,NS:OP871936), A/New York City/PV00046/2017 (EPI_ISL_1584
2341,
PB2:OP872049,PB1:OP872050,PA:OP872051,HA:OP872052,NP:
OP872053,NA:OP872054,M:OP872055,NS:OP872056), A/New York
City/PV01296/2018 (EPI_ISL_326915, PB2:OP913191,PB1:OP913192,PA:OP913193,HA:OP913194,NP:OP913195,NA:OP913196,M:OP913197), A/New
York City/PV02516/2019 (EPI_ISL_15842351, NA:MW650801,NS:MW
650802,PB1:MW650803,PB2:MW650804,HA:MW650805,PA:MW6508
06,M:MW650807,NP:MW650808), A/New York City/PV03878/2019
(EPI_ISL_15842352, PB2:OP871897,PB1:OP871898,PA:OP871899,HA:OP
871900,NP:OP871901,NA:OP871902,M:OP871903,NS:OP871904),
A/
New York City/PV00099/2017 (EPI_ISL_4072918, PA:MW651788,PB2:MW651789,HA:MW651790,PB1:MW651791,NS:MW651792,NA:MW651793,
NP:MW651794,M:MW651795), A/New York City/PV00105/2017 (EPI_
ISL_15842353, PB2:OP871953,PB1:OP871954,PA:OP871955,HA:OP8719
56,NP:OP871957,NA:OP871958,M:OP871959,NS:OP871960), A/Kansas/
14/2017 (EPI_ISL_403059), A/Singapore/INFIMH-16-0019/2016 (EPI_
ISL_13046488), A/Switzerland/8060/2017 (EPI_ISL_332305), A/Switzerland/9715293/2013
(EPI_ISL_230377),
A/Hong
Kong/4801/2014
(EPI_ISL_389028) and A/Aichi/2/1968 (EPI_ISL_123225). Source data are
provided with this paper.
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